The company is investing a total of $80m (€60m) on an expansion at the facility in New York, US, “to accommodate growth in [its] pipeline and commercial demand for [its] products,” Regeneron spokesperson Daniel Van Plew told our sister publication, in-Pharmatechnologist.com
On top of the four 10,000-litre bioreactors currently at the site, an extra two will be added in a new 65,000 sq ft commercial-scale manufacturing site.
Though Van Plew said the growth could not be attributed “to any one product or to any particular regulatory approval,” the facility makes the firms lead product Eylea, a treatment for wet age-related macular degeneration.
According to Regeneron’s Q2 2013 results, net sales of Eylea stood at $329.8m – up from $194m for the same period last year – comprising 72% of Regeneron’s total revenue for the quarter.
And Regeneron recently announced plans to boost monoclonal antibody production in Ireland with a deal that could see it buy a 400,000 sq ft facility in Limerick from computer manufacturer Dell. Read the full story here.